Physician profile
John S Townsend
NPI 1811948979
$4,461.82
in general payments reported to CMS, 2019-2025
14 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $159 · 2021: $104 · 2022: $214 · 2023: $299 · 2024: $10.86 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,328 · Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,328.00 |
| Food and Beverage | $328.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,346.99 | 2025 | Rs-4i Plus With Intersperse |
| Collegium Pharmaceutical, INC. | $172.59 | 2022-2023 | Belbuca |
| Electronic Waveform Lab, INC. | $167.64 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.24 | 2020 | |
| Ermi LLC | $116.61 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.29 | 2022-2023 | Relistor |
| Stryker Corporation | $112.16 | 2019 | |
| Microport Orthopedics INC | $105.02 | 2019 | |
| Averitas Pharma INC. | $70.00 | 2023 | Qutenza |
| Baudax Bio INC. | $50.07 | 2021 | |
| Grt US Holding, INC. | $28.90 | 2022 | |
| Novo Nordisk INC | $24.90 | 2019 | |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Emergent Biosolutions INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.